ClinicalTrials.gg
CompletedNCT01059825Updated Sep 13, 2018Results posted

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

A Phase 2 interventional study of Placebo to Ertugliflozin and Ertugliflozin 1 mg in Diabetes Mellitus, Type 2, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-09-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
10th of 28
375 · median 83
Started
2010
with 4 others
Phase 2
3 of 28
none open now
Registered
3rd of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 5 that started in 2010, is one of 3 in phase 2, and was the 3rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus. Participants in the study will receive 1 of 6 treatments for 12 weeks including 1 treatment with an approved drug (sitagliptin) for the treatment of Type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Phase 2
  • safety and efficacy study with ertugliflozin (PF-04971729, MK-8835)
  • Type 2 diabetes mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with type 2 diabetes on stable doses of background medicines for management of the diabetes; aged 18-70 years; between 23-45 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Participants with type 1 diabetes, heart attack or stroke in last 6-months, uncontrolled blood pressure, significant kidney disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
375 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days

    Drug: Placebo to Ertugliflozin · Drug: Placebo to Sitagliptin · Drug: Metformin

  • Experimental
    Ertugliflozin 1 mg

    Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days

    Drug: Placebo to Ertugliflozin · Drug: Ertugliflozin 1 mg · Drug: Placebo to Sitagliptin · Drug: Metformin

  • Experimental
    Ertugliflozin 5 mg

    Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days

    Drug: Placebo to Ertugliflozin · Drug: Ertugliflozin 5 mg · Drug: Placebo to Sitagliptin · Drug: Metformin

  • Experimental
    Ertugliflozin 10 mg

    Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days

    Drug: Placebo to Ertugliflozin · Drug: Ertugliflozin 5 mg · Drug: Placebo to Sitagliptin · Drug: Metformin

  • Experimental
    Ertugliflozin 25 mg

    Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days

    Drug: Placebo to Ertugliflozin · Drug: Ertugliflozin 25 mg · Drug: Placebo to Sitagliptin · Drug: Metformin

  • Active comparator
    Sitagliptin 100 mg

    Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days

    Drug: Placebo to Ertugliflozin · Drug: Sitagliptin 100 mg · Drug: Metformin

Interventions

  • DrugPlacebo to Ertugliflozin

    Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days

  • Tablet, 1 mg, once daily for 84 days

  • Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days

  • Tablet, 25 mg, once daily for 84 days

  • Tablet, 100 mg, once daily for 84 days

    Also known as: Januvia®, Tesavel®, Xelevia®, Ristaben®

  • DrugPlacebo to Sitagliptin

    Tablet, matching placebo to 100 mg, once daily for 84 days

  • Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).

    Also known as: Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®

06

What researchers measure

Primary outcomes

  1. Baseline Hemoglobin A1c (HbA1c)

    HbA1c is measured as percent.

    Time frame: Baseline

  2. Change From Baseline in HbA1c at Week 12

    HbA1c is measured as percent. The change from baseline is the Week 12 HbA1c percent minus the Week 0 HbA1c percent (last observation carried forward \[LOCF\]).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in HbA1C at Week 2

    HbA1c is measured as percent. The change from baseline is the Week 2 HbA1c percent minus the Week 0 HbA1c percent (LOCF).

    Time frame: Baseline and Week 2

  2. Change From Baseline in HbA1c at Week 4

    HbA1c is measured as percent. The change from baseline is the Week 4 HbA1c percent minus the Week 0 HbA1c percent (LOCF).

    Time frame: Baseline and Week 4

  3. Change From Baseline in HbA1c at Week 8

    HbA1c is measured as percent. The change from baseline is the Week 8 HbA1c percent minus the Week 0 HbA1c percent (LOCF).

    Time frame: Baseline and Week 8

  4. Baseline Body Weight

    Time frame: Baseline

  5. Percent Change From Baseline in Body Weight at Week 12

    The percent change from baseline is the (\[Week 12 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).

    Time frame: Baseline and Week 12

  6. Percent Change From Baseline in Body Weight at Week 2

    The percent change from baseline is the (\[Week 2 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).

    Time frame: Baseline and Week 2

  7. Percent Change From Baseline in Body Weight at Week 4

    The percent change from baseline is the (\[Week 4 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).

    Time frame: Baseline and Week 4

  8. Percent Change From Baseline in Body Weight at Week 8

    The percent change from baseline is the (\[Week 8 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).

    Time frame: Baseline and Week 8

  9. Baseline Systolic Blood Pressure

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.

    Time frame: Baseline

  10. Change From Baseline in Systolic Blood Pressure at Week 12

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).

    Time frame: Baseline and Week 12

  11. Change From Baseline in Systolic Blood Pressure at Week 2

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).

    Time frame: Baseline and Week 2

  12. Change From Baseline in Systolic Blood Pressure at Week 4

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).

    Time frame: Baseline and Week 4

  13. Change From Baseline in Systolic Blood Pressure at Week 8

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).

    Time frame: Baseline and Week 8

  14. Baseline Diastolic Blood Pressure

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.

    Time frame: Baseline

  15. Change From Baseline in Diastolic Blood Pressure at Week 12

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).

    Time frame: Baseline and Week 12

  16. Change From Baseline in Diastolic Blood Pressure at Week 2

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).

    Time frame: Baseline and Week 2

  17. Change From Baseline in Diastolic Blood Pressure at Week 4

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).

    Time frame: Baseline and Week 4

  18. Change From Baseline in Diastolic Blood Pressure at Week 8

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).

    Time frame: Baseline and Week 8

  19. Baseline Fasting Plasma Glucose

    Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

    Time frame: Baseline

  20. Change From Baseline in Fasting Plasma Glucose at Week 12

    The change from baseline is the Week 12 FPG minus the Week 0 fasting plasma glucose (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

    Time frame: Baseline and Week 12

  21. Change From Baseline in Fasting Plasma Glucose at Week 2

    The change from baseline is the Week 2 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

    Time frame: Baseline and Week 2

  22. Change From Baseline in Fasting Plasma Glucose at Week 4

    The change from baseline is the Week 4 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

    Time frame: Baseline and Week 4

  23. Change From Baseline in Fasting Plasma Glucose at Week 8

    The change from baseline is the Week 8 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

    Time frame: Baseline and Week 8

  24. Percentage of Participants Achieving HbA1c <7% at Week 12

    Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

    Time frame: Week 12

  25. Percentage of Participants Achieving HbA1C <6.5% at Week 12

    Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

    Time frame: Week 12

  26. Number of Participants Who Experienced an Advere Event (AE)

    An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin.

    Time frame: Up to 98 days

  27. Number of Participants Who Discontinued Study Medication Due to an AE

    An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin and excludes a temporary discontinuation of study medication.

    Time frame: Up to 84 days

07

Results

Posted Oct 4, 2017

Participant flow

Enrolled, Run-in Period
Participant flow — Enrolled, Run-in Period
MilestonePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mgMetformin Run-in
Started000000375
Completed000000328
Not completed00000047
Withdrew: Adverse event not related to study drug0000003
Withdrew: Did not meet entrance criteria00000014
Withdrew: Lost to follow-up0000005
Withdrew: Withdrawal by subject00000013
Withdrew: Other reason not specified0000007
Withdrew: Protocol violation0000005
Treatment Period
Participant flow — Treatment Period
MilestonePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mgMetformin Run-in
Started5454555555550
Completed4450494447520
Not completed104611830
Withdrew: Lost to follow-up2101200
Withdrew: Withdrawal by subject3015410
Withdrew: Other reason not specified1212000
Withdrew: Protocol violation0011110
Withdrew: Adverse event related to study drug1011000
Withdrew: Insufficient clinical response3000000
Withdrew: Adverse event not related to study drug0121110

Outcome measures

PrimaryBaseline Hemoglobin A1c (HbA1c)

HbA1c is measured as percent.

Time frame:
Baseline
Reported as:
Mean · Percent
Baseline Hemoglobin A1c (HbA1c)
PercentPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Baseline Hemoglobin A1c (HbA1c)8.08 ± 0.148.01 ± 0.177.88 ± 0.138.13 ± 0.178.30 ± 0.168.24 ± 0.15
PrimaryChange From Baseline in HbA1c at Week 12

HbA1c is measured as percent. The change from baseline is the Week 12 HbA1c percent minus the Week 0 HbA1c percent (last observation carried forward \[LOCF\]).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent
Change From Baseline in HbA1c at Week 12
PercentPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in HbA1c at Week 12-0.11 (-0.25 to 0.04)-0.56 (-0.69 to -0.42)-0.80 (-0.94 to -0.66)-0.73 (-0.87 to -0.58)-0.83 (-0.98 to -0.69)-0.87 (-1.01 to -0.73)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.002 (P-value is one-sided.) · Difference in least squares means: -0.45 · 80% CI -0.65 to -0.25ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.69 · 80% CI -0.89 to -0.49ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.62 · 80% CI -0.82 to -0.42ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.72 · 80% CI -0.93 to -0.52ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.76 · 80% CI -0.97 to -0.56ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in HbA1C at Week 2

HbA1c is measured as percent. The change from baseline is the Week 2 HbA1c percent minus the Week 0 HbA1c percent (LOCF).

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percent
Change From Baseline in HbA1C at Week 2
PercentPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in HbA1C at Week 20.00 (-0.08 to 0.07)-0.14 (-0.21 to -0.06)-0.29 (-0.36 to -0.21)-0.22 (-0.29 to -0.15)-0.17 (-0.25 to -0.10)-0.26 (-0.33 to -0.18)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.049 (P-value is one-sided.) · Difference in least squares means: -0.13 · 80% CI -0.24 to -0.03ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.29 · 80% CI -0.39 to -0.18ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.004 (P-value is one-sided.) · Difference in least squares means: -0.22 · 80% CI -0.32 to -0.11ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.020 (P-value is one-sided.) · Difference in least squares means: -0.17 · 80% CI -0.27 to -0.06ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.001 (P-value is one-sided.) · Difference in least squares means: -0.25 · 80% CI -0.36 to -0.15ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in HbA1c at Week 4

HbA1c is measured as percent. The change from baseline is the Week 4 HbA1c percent minus the Week 0 HbA1c percent (LOCF).

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percent
Change From Baseline in HbA1c at Week 4
PercentPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in HbA1c at Week 4-0.04 (-0.13 to 0.06)-0.40 (-0.50 to -0.31)-0.49 (-0.59 to -0.40)-0.48 (-0.57 to -0.38)-0.40 (-0.49 to -0.30)-0.48 (-0.57 to -0.38)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.37 · 80% CI -0.50 to -0.23ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.45 · 80% CI -0.59 to -0.32ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.44 · 80% CI -0.57 to -0.30ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.36 · 80% CI -0.49 to -0.22ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.44 · 80% CI -0.57 to -0.30ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in HbA1c at Week 8

HbA1c is measured as percent. The change from baseline is the Week 8 HbA1c percent minus the Week 0 HbA1c percent (LOCF).

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percent
Change From Baseline in HbA1c at Week 8
PercentPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in HbA1c at Week 8-0.10 (-0.22 to -0.02)-0.57 (-0.69 to -0.45)-0.76 (-0.88 to -0.64)-0.73 (-0.85 to -0.60)-0.75 (-0.87 to -0.62)-0.77 (-0.89 to -0.65)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.47 · 80% CI -0.64 to -0.30ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.66 · 80% CI -0.83 to -0.49ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.63 · 80% CI -0.80 to -0.45ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.65 · 80% CI -0.82 to -0.47ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.67 · 80% CI -0.84 to -0.50ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryBaseline Body Weight
Time frame:
Baseline
Reported as:
Mean · kg
Baseline Body Weight
kgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Baseline Body Weight83.78 ± 2.3783.44 ± 2.5785.74 ± 2.8282.28 ± 2.9381.81 ± 2.3485.52 ± 2.61
SecondaryPercent Change From Baseline in Body Weight at Week 12

The percent change from baseline is the (\[Week 12 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight at Week 12
Percent changePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Percent Change From Baseline in Body Weight at Week 12-0.75 (-1.18 to -0.32)-1.90 (-2.32 to -1.48)-2.50 (-2.92 to -2.07)-2.90 (-3.33 to -2.47)-2.66 (-3.10 to -2.23)-0.30 (-0.72 to 0.13)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.007 (P-value is one-sided.) · Difference in least squares means: -1.15 · 80% CI -1.75 to -0.55ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -1.75 · 80% CI -2.35 to -1.14ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -2.15 · 80% CI -2.76 to -1.54ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -1.91 · 80% CI -2.52 to -1.30ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.833 (P-value is one-sided.) · Difference in least squares means: 0.45 · 80% CI -0.15 to 1.06ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryPercent Change From Baseline in Body Weight at Week 2

The percent change from baseline is the (\[Week 2 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight at Week 2
Percent changePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Percent Change From Baseline in Body Weight at Week 2-0.24 (-0.46 to -0.02)-0.65 (-0.87 to -0.44)-1.36 (-1.59 to -1.14)-1.14 (-1.36 to -0.92)-1.11 (-1.33 to -0.88)0.21 (-0.01 to 0.43)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.043 (P-value is one-sided.) · Difference in least squares means: -0.42 · 80% CI -0.73 to -0.11ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -1.13 · 80% CI -1.44 to -0.81ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.90 · 80% CI -1.22 to -0.59ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -0.87 · 80% CI -1.18 to -0.55ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.967 (P-value is one-sided.) · Difference in least squares means: 0.45 · 80% CI 0.14 to 0.76ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryPercent Change From Baseline in Body Weight at Week 4

The percent change from baseline is the (\[Week 4 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight at Week 4
Percent changePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Percent Change From Baseline in Body Weight at Week 4-0.44 (-0.73 to -0.15)-1.20 (-1.48 to -0.92)-1.76 (-2.04 to -1.48)-1.68 (-1.97 to -1.39)-1.52 (-1.81 to -1.23)0.01 (-0.28 to 0.30)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.008 (P-value is one-sided.) · Difference in least squares means: -0.76 · 80% CI -1.17 to -0.36ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -1.32 · 80% CI -1.73 to -0.91ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -1.24 · 80% CI -1.65 to -0.83ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Odds ratio (or): -1.08 · 80% CI -1.49 to -0.67ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward..
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.922 (P-value is one-sided.) · Odds ratio (or): 0.45 · 80% CI 0.04 to 0.86ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryPercent Change From Baseline in Body Weight at Week 8

The percent change from baseline is the (\[Week 8 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight at Week 8
Percent changePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Percent Change From Baseline in Body Weight at Week 8-0.62 (-0.96 to -0.28)-1.65 (-1.98 to -1.32)-2.18 (-2.52 to -1.85)-2.30 (-2.64 to -1.96)-2.40 (-2.74 to -2.06)-0.38 (-0.71 to -0.05)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.003 (P-value is one-sided.) · Difference in least squares means: -1.03 · 80% CI -1.51 to -0.56ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -1.57 · 80% CI -2.04 to -1.09ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -1.68 · 80% CI -2.16 to -1.21ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -1.78 · 80% CI -2.26 to -1.30ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.741 (P-value is one-sided.) · Difference in least squares means: 0.24 · 80% CI -0.24 to 0.71ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryBaseline Systolic Blood Pressure

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.

Time frame:
Baseline
Reported as:
Mean · mmHg
Baseline Systolic Blood Pressure
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Baseline Systolic Blood Pressure126.7 ± 1.71126.5 ± 2.18127.9 ± 2.31125.8 ± 1.97124.9 ± 2.20126.6 ± 1.83
SecondaryChange From Baseline in Systolic Blood Pressure at Week 12

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Systolic Blood Pressure at Week 12
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Systolic Blood Pressure at Week 12-0.55 (-2.55 to 1.44)-2.69 (-4.63 to -0.75)-4.03 (-5.99 to -2.07)-3.43 (-5.43 to -1.43)-3.93 (-5.94 to -1.91)-1.09 (-3.05 to 0.87)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.163 (P-value is one-sided.) · Difference in least squares means: -2.13 · 80% CI -4.92 to 0.65ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.056 (P-value is one-sided.) · Difference in least squares means: -3.48 · 80% CI -6.28 to -0.68ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.096 (P-value is one-sided.) · Difference in least squares means: -2.88 · 80% CI -5.70 to -0.05ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.064 (P-value is one-sided.) · Difference in least squares means: -3.37 · 80% CI -6.21 to -0.53ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.403 (P-value is one-sided.) · Difference in least squares means: -0.54 · 80% CI -3.33 to 2.26ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in Systolic Blood Pressure at Week 2

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · mmHg
Change From Baseline in Systolic Blood Pressure at Week 2
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Systolic Blood Pressure at Week 2-1.93 (-3.73 to -0.12)-2.30 (-4.08 to -0.51)-4.73 (-6.57 to -2.89)-2.28 (-4.10 to -0.45)-5.39 (-7.23 to -3.55)-0.91 (-2.74 to 0.91)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.425 (P-value is one-sided.) · Difference in least squares means: -0.37 · 80% CI -2.91 to 2.17ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.082 (P-value is one-sided.) · Difference in least squares means: -2.81 · 80% CI -5.38 to -0.23ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.430 (P-value is one-sided.) · Difference in least squares means: -0.35 · 80% CI -2.92 to 2.21ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.043 (P-value is one-sided.) · Difference in least squares means: -3.47 · 80% CI -6.05 to -0.89ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.694 (P-value is one-sided.) · Difference in least squares means: 1.01 · 80% CI -1.55 to 3.58ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in Systolic Blood Pressure at Week 4

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mmHg
Change From Baseline in Systolic Blood Pressure at Week 4
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Systolic Blood Pressure at Week 4-2.57 (-4.31 to -0.82)-3.94 (-5.64 to -2.25)-5.15 (-6.86 to -3.44)-5.43 (-7.17 to -3.69)-3.33 (-5.09 to -1.57)-3.32 (-5.05 to -1.60)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.234 (P-value is one-sided.) · Difference in least squares means: -1.38 · 80% CI -3.81 to 1.05ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.087 (P-value is one-sided.) · Difference in least squares means: -2.59 · 80% CI -5.03 to -0.14ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.068 (P-value is one-sided.) · Difference in least squares means: -2.86 · 80% CI -5.33 to -0.40ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.346 (P-value is one-sided.) · Difference in least squares means: -0.77 · 80% CI -3.25 to 1.71ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.346 (P-value is one-sided.) · Difference in least squares means: -0.76 · 80% CI -3.21 to 1.70ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in Systolic Blood Pressure at Week 8

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change From Baseline in Systolic Blood Pressure at Week 8
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Systolic Blood Pressure at Week 8-0.44 (-2.42 to 1.55)-1.53 (-3.46 to 0.40)-2.85 (-4.80 to -0.90)-3.04 (-5.03 to -1.06)-3.30 (-5.31 to -1.30)-2.43 (-4.38 to -0.48)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.306 (P-value is one-sided.) · Difference in least squares means: -1.10 · 80% CI -3.87 to 1.67ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.133 (P-value is one-sided.) · Difference in least squares means: -2.41 · 80% CI -5.19 to 0.37ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.117 (P-value is one-sided.) · Difference in least squares means: -2.61 · 80% CI -5.42 to 0.20ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.097 (P-value is one-sided.) · Difference in least squares means: -2.87 · 80% CI -5.69 to -0.04ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.179 (P-value is one-sided.) · Difference in least squares means: -2.00 · 80% CI -4.78 to 0.79ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryBaseline Diastolic Blood Pressure

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.

Time frame:
Baseline
Reported as:
Mean · mmHg
Baseline Diastolic Blood Pressure
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Baseline Diastolic Blood Pressure79.14 ± 1.2478.95 ± 1.1478.19 ± 1.3678.45 ± 1.3278.61 ± 1.2479.15 ± 1.01
SecondaryChange From Baseline in Diastolic Blood Pressure at Week 12

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Week 12
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Diastolic Blood Pressure at Week 120.81 (-0.41 to 2.02)-1.12 (-2.30 to 0.06)-1.01 (-2.20 to 0.18)-3.18 (-4.40 to -1.97)-1.83 (-3.06 to -0.61)1.68 (0.49 to 2.87)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.072 (P-value is one-sided.) · Difference in least squares means: -1.93 · 80% CI -3.62 to -0.24ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.086 (P-value is one-sided.) · Difference in least squares means: -1.81 · 80% CI -3.51 to -0.11ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.002 (P-value is one-sided.) · Difference in least squares means: -3.99 · 80% CI -5.71 to -2.27ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.025 (P-value is one-sided.) · Difference in least squares means: -2.64 · 80% CI -4.37 to -0.92ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.746 (P-value is one-sided.) · Difference in least squares means: 0.88 · 80% CI -0.82 to 2.58ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in Diastolic Blood Pressure at Week 2

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Week 2
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Diastolic Blood Pressure at Week 2-0.57 (-1.69 to 0.56)-1.25 (-2.37 to -0.14)-1.26 (-2.41 to -0.12)-1.97 (-3.11 to -0.84)-3.01 (-4.16 to -1.86)0.92 (-0.22 to 2.06)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.289 (P-value is one-sided.) · Difference in least squares means: -0.69 · 80% CI -2.27 to 0.90ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.288 (P-value is one-sided.) · Difference in least squares means: -0.70 · 80% CI -2.31 to 0.91ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.130 (P-value is one-sided.) · Difference in least squares means: -1.41 · 80% CI -3.01 to 0.19ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.026 (P-value is one-sided.) · Difference in least squares means: -2.44 · 80% CI -4.05 to -0.84ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.883 (P-value is one-sided.) · Difference in least squares means: 1.49 · 80% CI -0.11 to 3.08ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in Diastolic Blood Pressure at Week 4

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Week 4
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Diastolic Blood Pressure at Week 4-0.80 (-1.80 to 0.21)-2.47 (-3.44 to -1.49)-3.08 (-4.07 to -2.10)-2.81 (-3.81 to -1.80)-2.10 (-3.11 to -1.09)-0.51 (-1.51 to 0.48)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.063 (P-value is one-sided.) · Difference in least squares means: -1.67 · 80% CI -3.07 to -0.27ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.019 (P-value is one-sided.) · Difference in least squares means: -2.29 · 80% CI -3.69 to -0.88ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.035 (P-value is one-sided.) · Difference in least squares means: -2.01 · 80% CI -3.43 to -0.59ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.121 (P-value is one-sided.) · Difference in least squares means: -1.30 · 80% CI -2.73 to 0.12ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.602 (P-value is one-sided.) · Difference in least squares means: 0.29 · 80% CI -1.13 to 1.70ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in Diastolic Blood Pressure at Week 8

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Week 8
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Diastolic Blood Pressure at Week 80.80 (-0.40 to 1.99)-1.40 (-2.56 to -0.24)-0.69 (-1.86 to 0.48)-2.23 (-3.42 to -1.04)-1.20 (-2.40 to 0.01)0.32 (-0.85 to 1.49)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.045 (P-value is one-sided.) · Difference in least squares means: -2.20 · 80% CI -3.86 to -0.54ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.126 (P-value is one-sided.) · Difference in least squares means: -1.49 · 80% CI -3.16 to 0.18ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.011 (P-value is one-sided.) · Difference in least squares means: -3.03 · 80% CI -4.72 to -1.34ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.066 (P-value is one-sided.) · Difference in least squares means: -1.99 · 80% CI -3.69 to -0.30ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.357 (P-value is one-sided.) · Difference in least squares means: -0.48 · 80% CI -2.15 to 1.19ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryBaseline Fasting Plasma Glucose

Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

Time frame:
Baseline
Reported as:
Mean · mg/dL
Baseline Fasting Plasma Glucose
mg/dLPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Baseline Fasting Plasma Glucose165.3 ± 5.65162.5 ± 6.75156.5 ± 5.79163.3 ± 6.30171.3 ± 7.69166.2 ± 6.70
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 12

The change from baseline is the Week 12 FPG minus the Week 0 fasting plasma glucose (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 12
mg/dLPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Fasting Plasma Glucose at Week 122.76 (-2.47 to 8.00)-18.23 (-23.32 to -13.14)-23.06 (-28.21 to -17.90)-31.47 (-36.71 to -26.24)-29.26 (-34.58 to -23.94)-17.29 (-22.43 to -12.15)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -20.99 · 80% CI -28.29 to -13.69ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided.P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -25.82 · 80% CI -33.17 to -18.47ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -34.23 · 80% CI -41.64 to -26.83ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -32.02 · 80% CI -39.49 to -24.56ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -20.05 · 80% CI -27.39 to -12.72ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 2

The change from baseline is the Week 2 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 2
mg/dLPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Fasting Plasma Glucose at Week 25.89 (0.50 to 11.27)-15.07 (-20.46 to -9.69)-15.68 (-21.19 to -10.17)-26.65 (-32.09 to -21.21)-16.44 (-21.97 to -10.91)-14.69 (-20.07 to -9.30)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -20.96 · 80% CI -28.58 to -13.34ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -21.57 · 80% CI -29.27 to -13.86ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -32.54 · 80% CI -40.20 to -24.88ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -22.33 · 80% CI -30.05 to -14.61ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -20.57 · 80% CI -28.19 to -12.96ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 4

The change from baseline is the Week 4 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 4
mg/dLPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Fasting Plasma Glucose at Week 45.17 (0.10 to 10.24)-16.91 (-21.84 to -11.99)-22.77 (-27.77 to -17.78)-27.95 (-33.02 to -22.88)-26.62 (-31.77 to -21.46)-18.00 (-22.98 to -13.03)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -22.09 · 80% CI -29.16 to -15.01ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -27.94 · 80% CI -35.06 to -20.83ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -33.12 · 80% CI -40.29 to -25.95ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -31.79 · 80% CI -39.02 to -24.56ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -23.17 · 80% CI -30.28 to -16.07ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 8

The change from baseline is the Week 8 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 8
mg/dLPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Change From Baseline in Fasting Plasma Glucose at Week 83.82 (-1.06 to 8.69)-18.25 (-22.99 to -13.51)-24.69 (-29.49 to -19.89)-31.59 (-36.46 to -26.71)-30.99 (-35.94 to -26.04)-18.93 (-23.71 to -14.15)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -22.07 · 80% CI -28.87 to -15.27ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -28.51 · 80% CI -35.35 to -21.67ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 10 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -35.40 · 80% CI -42.30 to -28.51ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -34.81 · 80% CI -41.76 to -27.86ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
  • Placebo vs Sitagliptin 100 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \<0.0005 is reported as 0.000.) · Difference in least squares means: -22.75 · 80% CI -29.58 to -15.92ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.
SecondaryPercentage of Participants Achieving HbA1c <7% at Week 12

Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving HbA1c <7% at Week 12
Percentage of participantsPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Percentage of Participants Achieving HbA1c <7% at Week 1215.644.042.938.636.243.1
SecondaryPercentage of Participants Achieving HbA1C <6.5% at Week 12

Laboratory measurements were performed after an overnight fast ≥8 hours in duration.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving HbA1C <6.5% at Week 12
Percentage of participantsPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mg
Percentage of Participants Achieving HbA1C <6.5% at Week 126.712.020.413.614.925.5
SecondaryNumber of Participants Who Experienced an Advere Event (AE)

An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin.

Time frame:
Up to 98 days
Reported as:
Number · Participants
Number of Participants Who Experienced an Advere Event (AE)
ParticipantsPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mgMetformin Run-in
Number of Participants Who Experienced an Advere Event (AE)29313029283082
SecondaryNumber of Participants Who Discontinued Study Medication Due to an AE

An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin and excludes a temporary discontinuation of study medication.

Time frame:
Up to 84 days
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Medication Due to an AE
ParticipantsPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mgMetformin Run-in
Number of Participants Who Discontinued Study Medication Due to an AE1132113

Adverse events

Collected over Up to 24 weeks (including 10-week run-in period, 12-week treatment period, and 2-week follow-up period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/54 (0%)13/54 (24.1%)
Ertugliflozin 1 mg—0/54 (0%)10/54 (18.5%)
Ertugliflozin 5 mg—2/55 (3.6%)14/55 (25.5%)
Ertugliflozin 10 mg—0/55 (0%)14/55 (25.5%)
Ertugliflozin 25 mg—1/55 (1.8%)10/55 (18.2%)
Sitagliptin 100 mg—1/55 (1.8%)12/55 (21.8%)
Metformin Run-in—2/375 (0.5%)30/375 (8%)
Most frequent serious events
Most frequent serious events
EventPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mgMetformin Run-in
Acute myocardial infarctionCardiac disorders0/540/541/550/551/550/550/375
CellulitisInfections and infestations0/540/541/550/550/550/550/375
SyncopeVascular disorders0/540/541/550/550/550/550/375
Coronary artery stenosisCardiac disorders0/540/540/550/550/551/550/375
Food allergyImmune system disorders0/540/540/550/550/550/551/375
Myocardial infarctionCardiac disorders0/540/540/550/550/550/551/375
Most frequent other events
Most frequent other events
EventPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mgMetformin Run-in
ArthralgiaMusculoskeletal and connective tissue disorders1/542/546/552/552/550/554/375
Urinary tract infectionInfections and infestations4/542/540/555/550/551/554/375
DiarrhoeaGastrointestinal disorders1/542/541/552/553/554/5514/375
Genital infection fungalInfections and infestations1/540/541/553/554/550/552/375
HeadacheNervous system disorders2/541/544/551/551/551/554/375
Upper respiratory tract infectionInfections and infestations2/542/542/553/553/552/551/375
Blood pressure increasedInvestigations2/541/541/550/551/553/550/375
HypoglycaemiaMetabolism and nutrition disorders0/540/543/551/551/550/555/375
DizzinessNervous system disorders0/540/540/551/550/553/551/375

Baseline characteristics

Of the 375 enrolled participants included in the metformin run-in period, 328 participants were randomized to 1 of 6 treatment groups.

Age, Customized
Age, Customized(Participants)PlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mgTotal
< 18 years0000000
18-44 years8106191347
45-64 years413642473933238
>= 65 years58777943
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 10 mgErtugliflozin 25 mgSitagliptin 100 mgTotal
Female242014241815115
Male303441313740213
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015 Jun;17(6):591-598. doi: 10.1111/dom.12460. Epub 2015 Mar 31. PubMed 25754396 ↗
  • Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2. PubMed 34213819 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Jan 2011, 10 months.

Results were first posted in Oct 2017, 6 years 8 months after primary completion. A results delay was requested in Nov 2012.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 10 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2010
First posted
Feb 1, 2010
StartActual
Feb 24, 2010
Primary completionActual
Jan 20, 2011
CompletionActual
Jan 20, 2011
Results delay requested
Nov 12, 2012
Results first posted
Oct 4, 2017
Last update
Sep 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01059825
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Feb 1, 2010
Start date
Feb 24, 2010
Primary completion
Jan 20, 2011
Completion
Jan 20, 2011
Results posted
Oct 4, 2017
Last update
Sep 13, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion